• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

便秘型肠易激综合征和慢性特发性便秘的治疗选择综述

Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation.

作者信息

Patel Sarah, Doerfler Bethany, Boutros Katerine, Ng Samson, Manuel Machelle, DeSimone Elayne

机构信息

Department of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA.

Rutgers University, Piscataway, NJ, USA.

出版信息

Int J Gen Med. 2021 Apr 21;14:1457-1468. doi: 10.2147/IJGM.S274568. eCollection 2021.

DOI:10.2147/IJGM.S274568
PMID:33907450
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8071080/
Abstract

Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are two common disorders of gut-brain interaction. Affected patients often first present to their primary care providers seeking care for symptoms of constipation, abdominal pain, and bloating, which have a significant impact on their health-related quality of life. These patients often require extensive counseling and reassurance, and knowledge of reliable diagnostic criteria and treatment options is imperative to managing their conditions. Family medicine practitioners, including nurse practitioners and physician assistants, are uniquely qualified to provide a diagnosis and safe, effective management of these disorders. This article reviews the latest evidence and provides practical advice related to diagnosis and management of IBS-C and CIC.

摘要

便秘型肠易激综合征(IBS-C)和慢性特发性便秘(CIC)是两种常见的肠脑互动障碍。受影响的患者通常首先会去找他们的初级保健提供者,寻求针对便秘、腹痛和腹胀症状的治疗,这些症状对他们的健康相关生活质量有重大影响。这些患者通常需要大量的咨询和安慰,了解可靠的诊断标准和治疗选择对于管理他们的病情至关重要。包括执业护士和医师助理在内的家庭医学从业者具备独特的资质来对这些疾病进行诊断并提供安全、有效的管理。本文回顾了最新证据,并提供了与IBS-C和CIC的诊断及管理相关的实用建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7e9/8071080/3b1e6a492b48/IJGM-14-1457-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7e9/8071080/9476a163e93a/IJGM-14-1457-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7e9/8071080/3b1e6a492b48/IJGM-14-1457-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7e9/8071080/9476a163e93a/IJGM-14-1457-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7e9/8071080/3b1e6a492b48/IJGM-14-1457-g0002.jpg

相似文献

1
Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation.便秘型肠易激综合征和慢性特发性便秘的治疗选择综述
Int J Gen Med. 2021 Apr 21;14:1457-1468. doi: 10.2147/IJGM.S274568. eCollection 2021.
2
The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden.以便秘为主的肠易激综合征和慢性特发性便秘的范围:美国评估症状、就医情况和疾病负担的调查
Am J Gastroenterol. 2015 Apr;110(4):580-7. doi: 10.1038/ajg.2015.67. Epub 2015 Mar 17.
3
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.便秘型肠易激综合征和慢性特发性便秘的现有及新出现的治疗方法:聚焦于促分泌剂。
Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27.
4
A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.一项基于社区队列的慢性特发性便秘与便秘型肠易激综合征直接医疗服务提供者医疗成本的病例对照比较。
J Med Econ. 2017 Mar;20(3):273-279. doi: 10.1080/13696998.2016.1253584. Epub 2016 Nov 10.
5
Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation.普卡必利治疗慢性特发性便秘和便秘型肠易激综合征:成人严重便秘安慰剂对照试验的事后分析。
Neurogastroenterol Motil. 2023 Sep;35(9):e14632. doi: 10.1111/nmo.14632. Epub 2023 Jun 18.
6
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.新型促动力和促分泌剂在慢性特发性便秘和便秘型肠易激综合征治疗中的应用。
Adv Ther. 2009 May;26(5):519-30. doi: 10.1007/s12325-009-0027-4. Epub 2009 May 14.
7
Lower and Upper Gastrointestinal Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation.便秘型肠易激综合征或慢性特发性便秘患者的上下消化道症状存在差异。
J Neurogastroenterol Motil. 2018 Apr 30;24(2):299-306. doi: 10.5056/jnm17112.
8
Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR).使用确定性链接的行政索赔和患者报告数据对便秘型肠易激综合征和慢性特发性便秘患者进行综合评估:慢性便秘和肠易激综合征 C 型治疗和结局真实世界研究平台(CONTOR)。
J Med Econ. 2020 Oct;23(10):1072-1083. doi: 10.1080/13696998.2020.1799816. Epub 2020 Aug 11.
9
Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade.患有便秘型肠易激综合征或慢性特发性便秘患者的合并症:对过去十年文献的综述。
Postgrad Med. 2013 Mar;125(2):40-50. doi: 10.3810/pgm.2013.03.2640.
10
Linaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.利那洛肽:一种治疗慢性便秘和便秘型肠易激综合征的新型疗法。
Gastroenterol Hepatol (N Y). 2012 Oct;8(10):653-60.

引用本文的文献

1
Raising Expectations in IBS-C Management.提高IBS-C管理的期望。
Gastroenterol Hepatol (N Y). 2025 Apr;21(4):218-231.
2
Improving Irritable Bowel Syndrome (IBS) Symptoms and Quality of Life with Quebracho and Chestnut Tannin-Based Supplementation: A Single-Centre, Randomised, Double-Blind, Placebo-Controlled Clinical Trial.使用基于破斧木和栗木单宁的补充剂改善肠易激综合征(IBS)症状和生活质量:一项单中心、随机、双盲、安慰剂对照临床试验。
Nutrients. 2025 Jan 31;17(3):552. doi: 10.3390/nu17030552.
3
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States.

本文引用的文献

1
Behavioral and Diet Therapies in Integrated Care for Patients With Irritable Bowel Syndrome.行为与饮食疗法在肠易激综合征综合治疗中的应用
Gastroenterology. 2021 Jan;160(1):47-62. doi: 10.1053/j.gastro.2020.06.099. Epub 2020 Oct 19.
2
The Humanistic and Economic Burden of Chronic Idiopathic Constipation in the USA: A Systematic Literature Review.美国慢性特发性便秘的人文和经济负担:一项系统文献综述
Clin Exp Gastroenterol. 2020 Jul 16;13:255-265. doi: 10.2147/CEG.S239205. eCollection 2020.
3
Laxative effects of wheat bran and psyllium: Resolving enduring misconceptions about fiber in treatment guidelines for chronic idiopathic constipation.
美国慢性特发性便秘患者处方药物持久性和依从性的真实世界研究。
J Manag Care Spec Pharm. 2024 Oct;30(10):1136-1148. doi: 10.18553/jmcp.2024.30.10.1136.
4
Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States.美国便秘型肠易激综合征患者负担及治疗前景综述
Clin Exp Gastroenterol. 2024 Aug 2;17:227-253. doi: 10.2147/CEG.S464375. eCollection 2024.
5
An exploration of fibre intake and bowel function in a sample of adults at an Irish university campus.对爱尔兰大学校园里一组成年人的纤维摄入量与肠道功能的探索。
Ir J Med Sci. 2024 Dec;193(6):2753-2760. doi: 10.1007/s11845-024-03764-9. Epub 2024 Aug 1.
6
Beneficial Effects of in the DCA Experimental Model of Irritable Bowel Syndrome in Rats.在大鼠肠易激综合征 DCA 实验模型中 的有益作用。
Nutrients. 2022 Dec 21;15(1):24. doi: 10.3390/nu15010024.
7
Intestinal anti-inflammatory and visceral analgesic effects of a extract in an experimental model of irritable bowel syndrome in rats.某提取物在大鼠肠易激综合征实验模型中的肠道抗炎和内脏镇痛作用。
Front Pharmacol. 2022 Sep 2;13:967644. doi: 10.3389/fphar.2022.967644. eCollection 2022.
麦麸和车前草的通便作用:消除慢性特发性便秘治疗指南中关于纤维的长期误解。
J Am Assoc Nurse Pract. 2020 Jan;32(1):15-23. doi: 10.1097/JXX.0000000000000346.
4
Homeopathy for treatment of irritable bowel syndrome.顺势疗法治疗肠易激综合征
Cochrane Database Syst Rev. 2019 Sep 4;9(9):CD009710. doi: 10.1002/14651858.CD009710.pub3.
5
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome.美国胃肠病学会关于肠易激综合征管理的专著
Am J Gastroenterol. 2018 Jun;113(Suppl 2):1-18. doi: 10.1038/s41395-018-0084-x.
6
Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.普卡必利治疗便秘型肠易激综合征的疗效、安全性和耐受性:两项 3 期随机临床试验结果。
Am J Gastroenterol. 2018 May;113(5):735-745. doi: 10.1038/s41395-018-0026-7. Epub 2018 Mar 15.
7
Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.随机临床试验:普卡那肽治疗慢性特发性便秘的疗效与安全性
Therap Adv Gastroenterol. 2017 Nov;10(11):837-851. doi: 10.1177/1756283X17734697. Epub 2017 Oct 25.
8
The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) Study: Results of an Online Questionnaire.更好地理解和认识慢性特发性便秘患者的脱节、经历和需求(BURDEN-CIC)研究:在线问卷的结果。
Adv Ther. 2017 Dec;34(12):2661-2673. doi: 10.1007/s12325-017-0633-5. Epub 2017 Nov 6.
9
SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada.研讨会报告:肠易激综合征和慢性特发性便秘的循证治疗方法:将新进展应用于日常实践——2016年10月16日美国胃肠病学会会议附属临床研讨会综述•内华达州拉斯维加斯
Gastroenterol Hepatol (N Y). 2017 Feb;13(2 Suppl 1):1-16.
10
Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.腹泻型肠易激综合征的现有及新出现的药物治疗:实践中的循证治疗
Therap Adv Gastroenterol. 2017 Feb;10(2):253-275. doi: 10.1177/1756283X16663396. Epub 2016 Sep 16.